Plasma stable, pH-sensitive non-ionic surfactant vesicles simultaneously enhance antiproliferative effect and selectivity of Sirolimus

Pharmaceutical Development and Technology

Volumn 20, Issue 3, 2015, Pages 279-287

  Ghanbarzadeh, Saeed ^a,b   Khorrami, Arash ^a,b   Pourmoazzen, Zhaleh ^c   Arami, Sanam ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AZARBAIJAN SHAHID MADANI UNIVERSITY   (Iran)

Author keywords

Antiproliferative effect; PH sensitive plasma stable niosome; Sirolimus

Indexed keywords

ALCOHOL; CHOLESTEROL HYDROGEN SUCCINATE; COPOLYMER; NIOSOME; NONIONIC SURFACTANT; RAPAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; CHOLESTEROL ESTER; CHOLESTERYL SUCCINATE; ITACONIC ACID; LIPOSOME; MACROGOL DERIVATIVE; POLYMER; SUCCINIC ACID DERIVATIVE; SURFACTANT;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SELECTIVITY; DRUG STABILITY; DRUG STORAGE; ENCAPSULATION; ENVIRONMENTAL TEMPERATURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; K562 CELL LINE; MTT ASSAY; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PLASMA; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL; ZETA POTENTIAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; MEDICINAL CHEMISTRY; PROCEDURES;

ANTIBIOTICS, ANTINEOPLASTIC; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL ESTERS; DRUG STABILITY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; K562 CELLS; LIPOSOMES; POLYETHYLENE GLYCOLS; POLYMERS; SIROLIMUS; SUCCINATES; SURFACE-ACTIVE AGENTS;

EID: 84927664721     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.860553     Document Type: Article

References (62)

1. Deng Z, Zhen Z, Hu X, et al. Hollow chitosan-silica nanospheres as pH-sensitive targeted delivery carriers in breast cancer therapy. Biomaterials. 2011; 32: 4976-4986
2. Felber AE, Dufresne M-H, Leroux J-C. pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv Drug Deliv Rev. 2012; 64: 979-992
3. He H, Chen S, Zhou J, et al. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials. 2013; 34: 5344-5358
4. Gerasimov OV, Boomer JA, Qualls MM, Thompson DH. Cytosolic drug delivery using pH- And light-sensitive liposomes. Adv Drug Deliv Rev. 1999; 38: 317-338
5. Simões S, Moreira JN, Fonseca C, et al. On the formulation of pHsensitive liposomes with long circulation times. Adv Drug Deliv Rev. 2004; 56: 947-965
6. Wu X, Kay Hoon L, Li Q-T. Stability and pH sensitivity of sulfatidecontaining phosphatidylethanolamine small unilamellar vesicles. Biochim Biophys Acta. 1996; 1284: 13-19
7. Drummond DC, Zignani M, Leroux J-C. Current status of pHsensitive liposomes in drug delivery. Prog Lipid Res. 2000; 39: 409-460
8. Li X-j, Schick M. Theory of tunable pH-sensitive vesicles of anionic and cationic lipids or anionic and neutral lipids. Biophys J. 2001; 80: 1703-1711
9. Simard P, Leroux J-C. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells. Int J Pharm. 2009; 381: 86-96
10. Yuba E, Harada A, Sakanishi Y, Kono K. Carboxylated hyperbranched poly(glycidol)s for preparation of pH-sensitive liposomes. J Control Release. 2011; 149: 72-80
11. Cazzola R, Viani P, Allevi P, et al. pH sensitivity and plasma stability of liposomes containing N-stearoylcysteamine. Biochim Biophys Acta Biomembr. 1997; 1329: 291-301
12. Marianecci C, Rinaldi F, Di Marzio L, et al. Interaction of pHsensitive non-phospholipid liposomes with cellular mimetic membranes. Biomed Microdevices. 2013; 15: 299-309
13. Carafa M, Di Marzio L, Marianecci C, et al. Designing novel pHsensitive non-phospholipid vesicle: characterization and cell interaction. Eur J Pharm Sci. 2006; 28: 385-393
14. Di Marzio L, Marianecci C, Cinque B, et al. pH-sensitive nonphospholipid vesicle and macrophage-like cells: binding, uptake and endocytotic pathway. Biochim Biophys Acta Biomembr. 2008; 1778: 2749-2756
15. Di Marzio L, Marianecci C, Petrone M, et al. Novel pH-sensitive non-ionic surfactant vesicles: comparison between Tween 21 and Tween 20. Colloids Surf B Biointerfaces. 2011; 82: 18-24
16. Vieira FP, Mesquita TL, Lara PCP, et al. ET AAS evaluation of the stability and pH-sensitivity of, pH-sensitive stealth liposomes containing cisplatin in mouse plasma. J Pharm Biomed Anal. 2013; 84: 135-139
17. Ducat E, Deprez J, Gillet A, et al. Nuclear delivery of a therapeutic peptide by long circulating pH-sensitive liposomes: Benefits over classical vesicles. Int J Pharm. 2011; 420: 319-332
18. Ishida T, Okada Y, Kobayashi T, Kiwada H. Development of pHsensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. Int J Pharm. 2006; 309: 94-100
19. Momekova D, Rangelov S, Yanev S, et al. Long-circulating, pHsensitive liposomes sterically stabilized by copolymers bearing short blocks of lipid-mimetic units. Eur J Pharm Sci. 2007; 32: 308-317
20. Ng K-y, Zhao L, Liu Y, Mahapatro M. The effects of polyethyleneglycol (PEG)-derived lipid on the activity of target-sensitive immunoliposome. Int J Pharm. 2000; 193: 157-166
21. Suzuki R, Takizawa T, Kuwata Y, et al. Effective anti-Tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm. 2008; 346: 143-150
22. Xu H, Deng Y, Chen D, et al. Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives. J Control Release. 2008; 130: 238-245
23. Yoshizawa Y, Kono Y, Ogawara K-i, et al. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-Tumor efficacy. Int J Pharm. 2011; 412: 132-141
24. Junyaprasert VB, Singhsa P, Suksiriworapong J, Chantasart D. Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid. Int J Pharm. 2012; 423: 303-311
25. Manosroi A, Wongtrakul P, Manosroi J, et al. Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids Surf B Biointerfaces. 2003; 30: 129-138
26. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998; 172: 33-70
27. Mehta SK, Jindal N, Kaur G. Quantitative investigation, stability and in vitro release studies of anti-TB drugs in Triton niosomes. Colloids Surf B Biointerfaces. 2011; 87: 173-179
28. Tavano L, Vivacqua M, Carito V, et al. Doxorubicin loaded magneto-niosomes for targeted drug delivery. Colloids Surf B Biointerfaces. 2013; 102: 803-807
29. Marianecci C, Rinaldi F, Esposito S, et al. Niosomes encapsulating Ibuprofen-cyclodextrin complexes: preparation and characterization. Curr Drug Targets. 2013; 14: 1070-1078
30. Marianecci C, Paolino D, Celia C, et al. Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts. J Control Release. 2010; 147: 127-135
31. Paolino D, Muzzalupo R, Ricciardi A, et al. In vitro and in vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery. Biomed Microdevices. 2007; 9: 421-433
32. Marianecci C, Rinaldi F, Mastriota M, et al. Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models. J Control Release. 2012; 164: 17-25
33. Carafa M, Marianecci C, Rinaldi F, et al. Span and Tween neutral and pH-sensitive vesicles: characterization and in vitro skin permeation. J Liposome Res. 2009; 19: 332-340
34. Marianecci C, Rinaldi F, Ingallina C, et al. Smart magnetic nanovesicles for theranostic application: preparation and characterization. Nuovo Cimento Soc Ital Fis, C. 2013; 36: 103-110
35. Hood E, Gonzalez M, Plaas A, et al. Immuno-Targeting of nonionic surfactant vesicles to inflammation. Int J Pharm. 2007; 339: 222-230
36. Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery - An overview. Acta Pharm Sin B. 2011; 1: 208-219
37. Paolino D, Cosco D, Muzzalupo R, et al. Innovative bolasurfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm. 2008; 353: 233-242
38. Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Release. 1994; 30: 1-15
39. Ghanbarzadeh S, Valizadeh H, Zakeri-Milani P. Sirolimus nano liposomes/optimization of sirolimus nano liposomes prepared by modified ethanol injection method using response surface methodology. Pharmind. 2013; In Press
40. Boratyńska M, Watorek E, Smolska D, et al. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc. 2007; 39: 2736-2739
41. Koehl GE, Schlitt HJ, Geissler EK. Rapamycin and tumor growth: mechanisms behind its anticancer activity. Transplant Rev. 2005; 19: 20-31
42. Nadiminti U, Arbiser JL. Rapamycin (sirolimus) as a steroidsparing agent in dermatomyositis. J Am Acad Dermatol. 2005; 52: S17-S19
43. Rangan GK, Nguyen T, Mainra R, et al. Therapeutic role of sirolimus in non-Transplant kidney disease. Pharmacol Ther. 2009; 123: 187-206
44. Watson CJE, Bradley JA. Sirolimus and everolimus: inhibitors of mammalian target of rapamycin in liver transplantation. Transplant Rev. 2006; 20: 104-114
45. Islambulchilar Z, Ghanbarzadeh S, Emami S, et al. Development and validation of an HPLC method for the analysis of sirolimus in drug products. Adv Pharm Bull. 2012; 2: 135-139
46. Bagheri M, Pourmoazzen Z, Entezami AA. Synthesis, characterization and liquid crystalline behavior of poly(monomethyl itaconate)s with new pendant cholesterol moieties. Iran Polym J. 2013; 22: 361-367
47. Ghanbarzadeh S, Arami S. Naproxen niosomes prepared with various nonionic surfactants mixed with cholesterol: effect of alkyl chain, hydrophilic lipophilic balance, phase transition temperature and cholesterol content. Pharmind. 2013; In Press
48. Ghanbarzadeh S, Valizadeh H, Zakeri-Milani P. Application of factorial designs and response surface methodology in formulation development of sirolimus liposome prepared by thin film hydration technique. BioImpacts. 2013; 3: 75-81
49. Ghanbarzadeh S, Arami S. Formulation and evaluation of piroxicam transferosomal gel: an approach for penetration enhancement. J Drug Deliv Sci Technol. 2013; In Press
50. Ghanbarzadeh S, Arami S. Enhanced transdermal delivery of diclofenac sodium via conventional liposomes, ethosomes, and transfersomes. Biomed Res Int. 2013; In Press
51. Marks DC, Belov L, Davey MW, et al. The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. Leuk Res. 1992; 16: 1165-1173
52. van de Loosdrecht AA, Beelen RHJ, Ossenkoppele GJ, et al A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods. 1994; 174: 311-320
53. Hong M, Zhu S, Jiang Y, et al. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release. 2009; 133: 96-102
54. Yang D-b, Zhu J-b, Huang Z-j, et al. Synthesis and application of poly(ethylene glycol)-cholesterol (Chol-PEGm) conjugates in physicochemical characterization of nonionic surfactant vesicles. Colloids Surf B Biointerfaces. 2008; 63: 192-199
55. Kaufmann S, Borisov O, Textora M, Reimhult E. Mechanical properties of mushroom and brush poly(ethylene glycol)-phospholipid membranes. Soft Matter. 2011; 17: 9267-9275
56. Di Marzio L, Esposito S, Rinaldi F, et al. Polysorbate 20 vesicles as oral delivery system: in vitro characterization. Colloids Surf B Biointerfaces. 2013; 104: 200-206
57. Ghanbarzadeh S, Valizadeh H, Zakeri-Milani P. The effects of lyophilization on the physico-chemical stability of sirolimus liposomes. Adv Pharm Bull. 2013; 3: 25-29
58. Jung SH, Kim SK, Jung SH, et al. Increased stability in plasma and enhanced cellular uptake of thermally denatured albumin-coated liposomes. Colloids Surf B Biointerfaces. 2010; 76: 434-440
59. Lück M, Pistel K-F, Li Y-X, et al. Plasma protein adsorption on biodegradable microspheres consisting of poly(d, l-lactide-co-glycolide), poly(l-lactide) or ABA triblock copolymers containing poly(oxyethylene): influence of production method and polymer composition. J Control Release. 1998; 55: 107-120
60. Norman ME, Williams P, Illum L. Influence of block copolymers on the adsorption of plasma proteins to microspheres. Biomaterials. 1993; 14: 193-202
61. Rejmanová P, Kopeček J, Duncan R, Lloyd JB. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers. Biomaterials. 1985; 6: 45-48
62. Yang Y, Pan D, Luo K, et al. Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy. Biomaterials. 2013; 4: 1008-1018